OVID Ovid Therapeutics Inc.

3.31
-0.18  -5%
Previous Close 3.49
Open 3.31
Price To Book 1.63
Market Cap 81605117
Shares 24,654,114
Volume 43,006
Short Ratio
Av. Daily Volume 84,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
OV101 (gaboxadol)
Fragile X syndrome
Phase 1/2 data released December 17, 2018 met primary endpoint of safety and tolerability.
OV935
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 trial planned for 2H 2019.
OV101 - NEPTUNE
Adolescents with Angelman syndrome
Phase 2 trial initiation announced September 24, 2018.
TAK-935/OV935
Developmental and Epileptic Encephalopathies (dEE) - younger patient population
Phase 1b/2a enrolment to be completed 2H 2019.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

SEC Filings

  1. 8-K - Current report 19512118
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19509588
  3. 8-K - Current report 19508418
  4. 8-K - Current report 181237055
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181226382
  6. 8-K - Current report 181218947
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168266
  8. 8-K - Current report 181168188
  9. 8-K - Current report 181137926
  10. 8-K - Current report 181095987